WilmerHale Counsels Merrimack in $25M Debt Facility

  • 7.6.2018

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a clinical-stage oncology company focused on biomarker-defined cancers, announced on July 2, 2018, the closing of a $25 million term loan with Hercules Capital (NYSE:HTGC), $15 million of which was funded at closing. Merrimack's funds are projected to help the company's planned operations into the first quarter of 2020.

The WilmerHale team representing Merrimack is led by Jamie Class, and includes John Sigel and Brandt Tierney.

Read Merrimack’s press release regarding the financing.

Not sure where to start?

Let our Knowledge Navigator direct you to content specific to where you are on your journey.

Get Started!
Featured
blog-launch-550x370

This blog post explores certain specific terms in term sheets that will create legally binding obligations.

Schall launch feature

Partner Gary Schall shares some practical advice about term sheets: Don’t attempt any transaction without one.

Rss Feed
2.21.2025
Write Warz developers on how creative writing makes a hilarious party game 
2.21.2025
Supergiant Games battles back accusations it is working around SAG-AFTRA strike 
2.21.2025
The remarkable banter of Cory Barlog and Neil Druckmann on the creative process 
Build
Document Generator  
Startup Dictionary  
2.20.2025
Corporate Transparency Act: Judge Clears Way for CTA; Reporting Requirements Back in Effect
2.12.2025
Corporate Transparency Act: It’s Still Paused (For Now)
12.27.2024
Corporate Transparency Act: Preliminary Injunctive Relief Reinstated by Fifth Circuit (For Now)